← Browse by Condition
Medical Condition
castration resistant prostate carcinoma
Total Trials
4
Recruiting Now
4
Trial Phases
Phase 2, Phase 3, Phase 1
ClinicalMetric tracks all active clinical trials for castration resistant prostate carcinoma sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.
- Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
- Phase 1–4 studies from early safety trials to post-marketing surveillance
- NIH, pharmaceutical sponsor, and academic medical center studies worldwide
- AI-powered plain-language summary available for every trial listing
Frequently Asked Questions — castration resistant prostate carcinoma Clinical Trials
How many clinical trials are currently recruiting for castration resistant prostate carcinoma?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for castration resistant prostate carcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for castration resistant prostate carcinoma?
castration resistant prostate carcinoma research spans Phase 1 (1 trial), Phase 2 (1 trial), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a castration resistant prostate carcinoma clinical trial?
Eligibility criteria for castration resistant prostate carcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 1
Phase 2 1
Phase 3 1
Top Sponsors
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT04489719
Recruiting
Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer
Enrollment
48 pts
Location
United States
Sponsor
University of Washington
NCT06632977 Phase 2
Recruiting
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
Enrollment
474 pts
Location
United States
Sponsor
Alliance for Clinical Trials i...
NCT06470243 Phase 3
Recruiting
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
Enrollment
528 pts
Location
United States
Sponsor
SWOG Cancer Research Network
NCT05805371 Phase 1
Recruiting
PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer
Enrollment
21 pts
Location
United States
Sponsor
City of Hope Medical Center
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology